Africa CDC Calls Oct. 28 Ebola Crisis Meeting as 9,500 Cases Spread to Nigeria
Updated
Updated · DW (English) · Oct 22
Africa CDC Calls Oct. 28 Ebola Crisis Meeting as 9,500 Cases Spread to Nigeria
3 articles · Updated · DW (English) · Oct 22
Summary
An extraordinary virtual meeting of African health officials will be held on Oct. 28 after Ebola reached Nigeria, the fourth country hit in the latest outbreak.
More than 9,500 infections and nearly 4,750 deaths have been recorded since May in Democratic Republic of Congo, in what WHO calls the fastest-growing Ebola outbreak ever.
Nigeria is tracing 44 contacts after confirming Bundibugyo virus in a woman who returned from Uganda; officials from both countries are still investigating where she was exposed.
Bundibugyo has no approved vaccines or treatments, and Africa CDC said the outbreak is now affecting central, eastern and western Africa, underscoring calls for continent-wide coordination.
As nations clash over the outbreak's origin, what hidden dangers does this new zoonotic Ebola spillover pose to global travel?
Can the $2.9 billion global pledge reach the conflict-ridden epicenter before this unprecedented Ebola strain spreads further?
With no approved vaccine, how did a medically evacuated patient in Germany survive this deadly, fast-moving Ebola strain?
2026 Bundibugyo Ebola Crisis: Unprecedented Regional Spread, Vaccine Gaps, and Economic Fallout in Africa
Overview
In October 2026, the Ebola outbreak spread to West Africa when a foreign diplomat traveled from Uganda to Abuja, Nigeria, and was later confirmed to have the Bundibugyo strain. Initial diagnostic failures delayed public health alerts, allowing the virus to move silently along transport networks. Nigerian authorities quickly identified high-risk contacts and enforced strict travel restrictions, while the DRC faced a major outbreak complicated by armed conflict and community distrust, leading to many deaths outside health facilities and high child mortality. With no approved Bundibugyo vaccine, WHO began emergency trials, but economic shocks, disrupted healthcare, and funding transparency issues deepened the crisis across the region.